Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on March 18, 2014, reporting events occurring on March 18 and March 20, 2014. The filing details the entry into a material definitive agreement regarding a secondary public offering of common stock by selling stockholders.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. The transaction described is a secondary offering where the Company does not receive proceeds.
- Shares Offered: 9,000,000 shares of Common Stock by Selling Stockholders.
- Offering Price: $7.10 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 1,350,000 additional shares.
- Company Proceeds: $0 (The Company will not sell shares or receive proceeds).
- Expected Closing Date: On or about March 26, 2014.
Material Changes
The primary material change is the execution of an underwriting agreement with Jefferies LLC and Stifel, Nicolaus & Company, Incorporated. This agreement facilitates the sale of existing shares by selling stockholders pursuant to a shelf registration statement (No. 333-193558) declared effective on February 3, 2014. There are no reported changes to the Company's operational financials in this filing.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of operational risks. The transaction is subject to customary closing conditions. The Underwriting Agreement includes customary representations, warranties, covenants, and indemnification obligations for the Company, Selling Stockholders, and Underwriters regarding liabilities under the Securities Act of 1933.
Investor Verification Checklist
- Verify the final closing date of the offering (expected March 26, 2014) and whether the over-allotment option was exercised.
- Confirm the identity of the Selling Stockholders in Schedule A of the Underwriting Agreement to assess potential dilution impact on remaining shareholders.
- Review the attached press releases (Exhibits 99.1 and 99.2) for any additional context on the selling stockholders' intentions.
- Check subsequent filings for any changes to the Company's capital structure resulting from this transaction.